SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending amidst mixed community sentiment following recent earnings and a potential bidding war with Pfizer for Metsera. While some investors see the dip as a buying opportunity, citing strong fundamentals and potential catalysts like oral pill approval and a Trump administration deal, others express concern over competition and management strategy. Discussions revolve around the company's valuation relative to competitors like Eli Lilly and potential market-moving news.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart ($UPST) is trending due to a significant after-hours drop following its latest earnings report, despite some positive metrics; the report included revenue -.9%, EPS +23.5%. The community is debating the validity of Upstart's AI-driven lending model and its loan portfolio, with some questioning the company's future prospects in the face of broader economic uncertainty and rising interest rates. Some community members expect a run up to earnings while others are planning to short.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid mixed community sentiment, with discussions revolving around fraud accusations against the founder and concerns over token unlocks. While some community members express concerns about potential scams and dilution, others remain bullish, citing partnerships and the potential of the super app. The conversation also includes discussion of the broader market and its impact on ZBCN.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending amid discussions of a potential short squeeze, fueled by high short interest and a recent earnings report that sparked debate about the company's turnaround. The community is weighing the potential for a squeeze against underlying financial concerns and the broader market's volatility, with some drawing comparisons to past meme stock rallies.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION is trending amid community discussions about potential backing from CZ, with some traders expressing excitement and others cautioning against potential pump-and-dump schemes. The conversation includes speculation on price movements and comparisons to other cryptocurrencies, particularly within the decentralized exchange (DEX) space. Some users are also mentioning and promoting other coins like $SLAP, $WAGMI, and $ICP.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to mixed sentiment following its recent earnings report; despite beating expectations, concerns over revenue guidance and competition in the AI chip market are weighing on the stock. The community is actively debating AMD's valuation, growth prospects, and potential impact from export restrictions to China, while analysts adjust price targets to reflect both optimism and caution.

Opera Ltd. engages in the provision of web browsers through its subsidiaries. Its products include Opera browser for Windows, iOS, and Linux computers, as well as the mobile apps Opera for Android, Opera Mini, Opera Touch, and Opera News. The company was founded in 1995 and is headquartered in Oslo, Norway.

Opera Ltd - ADR

Opera Ltd

OPRA is trending as investors debate its current valuation and future prospects following recent earnings. Community members are actively discussing the company's AI initiatives and potential for growth in the browser market. Some see it as undervalued, citing strong fundamentals and a high dividend yield, while others express concerns about revenue and market competition.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending following earnings, with discussions focused on its growth, margins, and AI prospects despite a weaker-than-expected guide which the community believes is an overreaction and presents a buying opportunity. Some traders believe the company is overly punished while others point to broader sector valuation concerns and debate its potential for a quick rebound and comparisons with competitors like NVDA. The community is actively debating the revenue beat and forward guidance.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is trending as investors discuss its potential growth catalysts, including its upcoming Investor Day and net interest income outlook. Bullish Elliott Wave technical analysis is circulating, while others point to the potential impact of interest rate cuts on the financial sector. Some traders are closely watching options flow and technical patterns for short-term opportunities.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors discuss its potential following recent earnings and the acquisition of Marigold. Community members highlight the company's predictable growth, strong ROI for marketing spend, and potential partnership with OpenAI. Despite some volatility and a recent dip, many believe ZETA is undervalued and poised for significant growth, especially with the upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Viking Therapeutics, Altria, Zoom, and ProFrac Holdings...

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 4, 2025 SAN DIEGO, Nov. 4, 2025...

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Equity

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in...

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

<ul class="summary-bullets"><li>Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share.&nbsp;</li><li>Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.</li><li>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule.</li></ul>Viking Therapeutics (VKTX) received a price target hike from Morgan Stanley on Thursday on the heels of positive third-quarter updates.&nbsp;Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. The new price target represents a potential upside of 225% from the stock’s closing price on Wednesday.<h2 class="st-heading-2">Morgan Stanley’s Take</h2>The analyst noted that two of the company’s late-stage trials for subcutaneous VK2735 are enrolling ahead of schedule, and the management plans to meet with the U.S. Food and Drug Administration for oral VK2735 in Q4 with a late-stage study start targeted soon after. The firm is "encouraged by swift execution across programs," the analyst added.Viking CEO Brian Lian said on Thursday that the company is expected to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in the first quarter of 2026. The VANQUISH late-stage program, including trials of Viking's subcutaneous formulation of VK2735 in patients with obesity and obesity with type 2 diabetes, was initiated in the second quarter.Viking on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302591893.html">reported</a> a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share, according to data from Fiscal AI. The company pinned the rise in net loss for the three months ended Sept. 30, 2025, to the increase in research and development expenses.The company ended the quarter with a cash position of $715 million, which it believes provides sufficient resources to develop VK2735 through the VANQUISH clinical trials and to continue development of additional clinical programs in its pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/VKTX">VKTX shares</a> soared 7% at the time of writing. On Stocktwits, retail sentiment around VKTX jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels. Retail chatter around the stock rose 197% over the past 24 hours, as of Thursday morning, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:620/63;" src="data:image/png;base64,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" width="620" height="63" alt="VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>VKTX's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>VKTX stock is down by 16% this year and by 44% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside

Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.89	--	--	N/A
Q3 '25	-$0.70	-$0.81	-15.17%	MISSED
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED
Q1 '25	-$0.33	-$0.41	-25.00%	MISSED
Q4 '24	-$0.27	-$0.32	-17.65%	MISSED

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc